Merck's 87% stock gain reflects investor confidence in its clinical pipeline and new product launches, even as revenue growth shows signs of slight deceleration heading into 2026.
Merck's stock nearly doubled on pipeline progress, but revenue growth remains steady and guidance slightly decelerates.
Johnson & Johnson is mentioned as a peer with a 56% return over the same period.
Pfizer is mentioned as a peer with a 23% return over the same period.
Merck stock has surged 87% over the past year, significantly outperforming peers like Johnson & Johnson and Pfizer. While revenue growth remains steady at 4.6%, investors are aggressively repricing the company based on successful clinical trial results and a robust pipeline of new products. Management is actively preparing for the 2028 patent cliff for its flagship drug, Keytruda, by accelerating the development of new commercial opportunities.
Merck's outperformance is attributed to tangible clinical evidence, including the FDA approval of Lipfendra and positive Phase III results for its TROP2 antibody-drug conjugate and tulisokibart.
Management is positioning the 2028 patent expiration as a manageable 'hill' rather than a 'cliff,' relying on a pipeline of over 20 new products representing $70 billion in commercial opportunity.